ORKA (Oruka Therapeutics, Inc.) Stock Financials & Earnings

ORKAOruka Therapeutics, Inc.

Mkt Cap$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$109M

EPS (TTM)-$3.31

Free Cash Flow (TTM)-$85M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Next: Q4 2025 · Mar 12

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$0	-$29K	-$2M
Q1 23	$0	-$29K	-$2M
Q2 23	$0	-$29K	-$2M
Q3 23	$0	-$30K	-$2M
Q4 23	$0	-$23K	-$2M
Q1 24	$0	-$19K	-$2M
Q2 24	$0	$0	-$21M
Q3 24	$0	$0	-$29M
Q4 24	$0	$0	-$38M
Q1 25	$0	$0	-$25M
Q2 25	$0	$0	-$28M
Q3 25	$0	$0	-$34M

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 22	$266K	—	—	$1M
Q1 23	$390K	—	—	$1M
Q2 23	$254K	—	—	$2M
Q3 23	$322K	—	—	$2M
Q4 23	$47K	—	—	$2M
Q1 24	$165K	$2M	—	—
Q2 24	$19M	—	—	$3M
Q3 24	$26M	$4M	—	—
Q4 24	$32M	$6M	$327K	—
Q1 25	$20M	$5M	—	—
Q2 25	$24M	$4M	—	—
Q3 25	$29M	$5M	—	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$42M	$0	$42M
Q1 23	$41M	$0	$41M
Q2 23	$40M	$0	$40M
Q3 23	$38M	$0	$38M
Q4 23	$37M	$0	$37M
Q1 24	$36M	$0	$36M
Q2 24	$33M	$0	$33M
Q3 24	$411M	$0	$411M
Q4 24	$62M	$314M	$376M
Q1 25	$84M	$266M	$349M
Q2 25	$65M	$263M	$328M
Q3 25	$91M	$258M	$349M

Shares Outstanding